# Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

> **NCT00944047** · PHASE2 · COMPLETED · sponsor: **University of Kansas Medical Center** · enrollment: 32 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** trastuzumab
- **DRUG:** Doxorubicin
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** Growth Factor Support
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT00944047
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2014-05
- **Final completion:** 2017-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00944047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00944047, "Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00944047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*